

Please type a plus sign (+) inside this box → ☐

PTO/SB/82 (05/03)  
Approved for use through 11/30/2005. OMB 0651-0035  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REVOCATION OF POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/211,715
Filing Date	12/14/1998
First Named Inventor	Fahad Al-Obeidi
Group Art Unit	1653
Examiner Name	Samuel W. Liu
Attorney Docket Number	P26,835-D-USA

**RECEIVED**

**SEP 15 2003**

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

☒ A Power of Attorney or Authorization of Agent is submitted herewith.

OR

☐ Please change the correspondence address for the above-identified application to:

☐ Customer Number

OR

Place Customer  
Number Bar Code  
Label here

☐ Firm or  
Individual Name

Address

Address

City

Country

State

ZIP

Telephone

Fax

I am the:

☐ Applicant/Inventor

☒

Assignee of record of the entire interest. See 37 CFR 3.71  
Certificate under 37CFR 3.73(b) is enclosed (Form PTO/SB/96)

### SIGNATURE of Applicant or Assignee of Record

Name **Ross J. Oehler**

Signature

Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Please type a plus sign (+) inside this box


+

PTO/SB/81 (05-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/211,715
Filing Date	12/14/1998
First Named Inventor	Fahad Al-Obeidi
Group Art Unit	1653
Examiner Name	Samuel W. Liu
Attorney Docket Number	P26,835-D USA

RECEIVED

SEP 15 2003

TECH CENTER 1000/2800

I hereby appoint:

☒ Practitioners at Customer Number

23,307

Place Customer  
Number Bar Code  
Label here

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number.

OR

☐ Practitioner(s) at Customer Number.

Place Customer  
Number Bar Code  
Label here

OR

<input type="checkbox"/> Firm or Individual Name				
Address				
Address				
City		State		Zip
Country				
Telephone		Fax		

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

## SIGNATURE of Applicant or Assignee of Record


Name	Ross J. Oehler
Signature	
Date	8/7/03

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



**STATEMENT UNDER 37 CFR 3.73(b)**

RECEIVED

Applicant/Patent Owner: Al-Obeidi, et al.

SEP 15 2003

Application No./Patent No.: 09/211,715

Filed/Issue Date: 12/14/1998

TECH CENTER 1600/2200

Entitled: **FACTOR Xa INHIBITORS**

Aventis Pharmaceuticals, Inc., a

corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

- A. [ ] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. [✓] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Fahad Al-Obeidi, et al. To: Selectide Corporation  
The document was recorded in the United States Patent and Trademark Office at  
Reel 009953, Frame 0441, or for which a copy thereof is attached.
2. From: Selectide Corporation To: Aventis Pharmaceuticals, Inc.  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

[ ] Additional documents in the chain of title are listed on a supplemental sheet.

[✓] Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

8/7/03  
Date

\_\_\_\_\_  
Telephone number

Ross J. Oehler  
Typed or printed name

[Signature]  
Signature

Assistant Secretary  
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE D FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# Delaware

PAGE 1

*The First State*


I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"BLUE RIDGE LABORATORIES, INC.", A DELAWARE CORPORATION,

"MARION MERRELL INTERCONTINENTAL LTD.", A DELAWARE CORPORATION,

"SELECTIDE CORPORATION", A DELAWARE CORPORATION,

WITH AND INTO "AVENTIS PHARMACEUTICALS INC." UNDER THE NAME OF "AVENTIS PHARMACEUTICALS INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE EIGHTEENTH DAY OF DECEMBER, A.D. 2000, AT 3:01 O'CLOCK P.M.



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

0613109 8100M

AUTHENTICATION: 2276540

030124398

DATE: 02-26-03

**CERTIFICATE OF OWNERSHIP AND MERGER**

**MERGING**

**BLUE RIDGE LABORATORIES, INC.**  
(a Delaware corporation) *and*

**SELECTIDE CORPORATION**  
(a Delaware corporation) *and*

**MARION MERRELL INTERCONTINENTAL LTD.**  
(a Delaware corporation)

**INTO**

**AVENTIS PHARMACEUTICALS INC.**  
(a Delaware corporation)

Aventis Pharmaceuticals Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as the "Corporation") does hereby certify that:

**FIRST:** The Corporation was incorporated on July 9, 1964 pursuant to the General Corporation Law of the State of Delaware.

**SECOND:** The Corporation is the owner of all of the issued and outstanding shares of stock of Blue Ridge Laboratories, Inc., Selectide Corporation and Marion Merrell Intercontinental Ltd. (the "Subsidiaries")

**THIRD:** The Corporation, by the following resolutions, duly adopted by the unanimous written consent of all of the members of the Board of Directors dated November 15, 2000, authorized the merger:

**RESOLVED,** that Aventis Pharmaceuticals Inc. hereby merges into itself Blue Ridge Laboratories Inc., Selectide Corporation and Marion Merrell Intercontinental Ltd. and assumes of the obligations of such wholly-owned Subsidiaries ; and

**FURTHER RESOLVED**, that the merger shall be effective upon filing with the Secretary of State of Delaware; and

**FURTHER RESOLVED**, that the proper officers of this Corporation be and hereby are authorized and directed to make and execute a Certificate of Ownership and Merger setting forth a copy of the resolutions to merge said subsidiary and assume its liabilities and obligations, and the date of adoption thereof, and to cause the same to be filed with the Secretary of State of Delaware and do all acts and things necessary, whether within or without the State of Delaware, which may be necessary and proper to effect said merger.

**IN WITNESS WHEREOF**, said Corporation has caused this Certificate to be executed by its President on this 29<sup>th</sup> day of November 2000.

**AVENTIS PHARMACEUTICALS INC.**

By: Gerald P. Belle  
Gerald P. Belle, President